Teva announces FDA approval for asthma injection, Cinqair | Pharmafile
cinqaero - Twitter Search / Twitter
Subcutaneous Cinqair results add to Teva's troubles
Brand name: Auvi-Q
FDA Will Review Teva's BLA for Asthma Drug Reslizumab
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Cinqair (reslizumab): Basics, Side Effects & Reviews
Dosing and Administration
Upcoming Reslizumab PDUFA- Approval Odds, And What It Means For Teva (NYSE: TEVA) | Seeking Alpha
Injectable asthma drug reslizumab approved by European Commission - The Pharmaceutical Journal
NICE changes mind and backs new drug for severe asthma | Nursing Times
Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation - Respiratory Medicine
Reslizumab – All About Drugs
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
New Severe Asthma Rx Gets Green Light | RxWiki
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison - Journal of Allergy and Clinical Immunology
Reslizumab | New Drug Approvals
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice - CHEST
Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study - The Journal of Allergy and Clinical Immunology: In Practice
